Drugs / Mino-Lok
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02901717 | Feb 2018 → Dec 2022 | prosthesis-related infectious disease | Leonard-Meron Biosciences, Inc. | Unknown | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-21 | Citius Pharmaceuticals, Inc. | Results Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution citiuspharma.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-21 | Citius Pharmaceuticals, Inc. | Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution citiuspharma.com ↗ |
| 2024-01-02 | Citius Pharmaceuticals, Inc. | Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters citiuspharma.com ↗ |
| 2023-08-10 | Citius Pharmaceuticals, Inc. | Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial citiuspharma.com ↗ |
| 2023-04-24 | Citius Pharmaceuticals, Inc. | Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date citiuspharma.com ↗ |
| 2022-05-06 | Citius Pharmaceuticals, Inc. | Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally citiuspharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mino-Lok | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02901717 ↗ |
| Known as | Mino-Lok Therapy | “Mino-Lok Therapy (MLT)” NCT02901717 ↗ |
| Known as | MLT | “Mino-Lok Therapy (MLT)” NCT02901717 ↗ |